Loading
institutionsInstitution
Gustave Roussy
Gustave Roussy, outside Paris, is Europe's largest cancer centre; its DITEP phase 1 unit and its breast antibody-drug conjugate and immunotherapy trials (trastuzumab deruxtecan, datopotamab deruxtecan) make it a lead site for industry studies, and it created the ESMO-MCBS scale for grading how much benefit a new drug offers.
Overview
Gustave Roussy in Villejuif, outside Paris, is Europe's largest cancer centre and ranks sixth in the Newsweek/Statista World's Best Specialized Hospitals list for oncology. It houses the DITEP phase 1 unit, holds a Paris-Saclay affiliation, and has led breast antibody-drug conjugate work on trastuzumab deruxtecan and datopotamab deruxtecan alongside a strong immuno-oncology programme, with Fabrice André, Caroline Robert, Laurence Albiges and Martin Schlumberger among its clinicians. OnCo links it to PEACE-1 and ESTIMABL2, to the Inter-B-NHL Ritux 2010 paediatric lymphoma trial, to the ITCC paediatric network, and to ideas on microbiome transplant and the timing of immunotherapy dosing. How an academic centre keeps independent judgement while leading so many industry-sponsored trials is a live question. Its phase 1 unit is the part most visitors come to see.
Location
Villejuif, FR
Type
cancer center
Website
Newsweek 2026 oncology rank
#6
OnCo score
#11 · 128 points (54 Newsweek + 0 NCI + 74 from 37 linked objects) · ranking
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-09-24.
Matched to Institut Gustave Roussy, including child institutions. 1,862 works · 31,707 citations · 71% open access · 21% clinical trials · 2% reviews.
Oncology works per year
3782022
4062023
4012024
3982025
2792026
Most works
- Caroline Robert114 works
- Antoine Hollebecque93 works
- Benjamin Besse89 works
- Barbara Pistilli78 works
- Fabrice André74 works
- Aurélien Marabelle70 works
- Michel Pierre Ducreux69 works
- Fabrice Barlesi63 works
- Alexandra F. Leary61 works
- Inês Vaz-Luís60 works
Most cited
- Phase 1 (DITEP)
- Breast ADC trials
- Immuno-oncology
Alexander Eggermont
Chief Scientific Officer, Princess Máxima Center; Professor, Utrecht; former EORTC President
MelanomaAdjuvant immunotherapySurgical oncology
Surgical oncologist who led the EORTC adjuvant ipilimumab and pembrolizumab trials in melanoma.
Aurélien Marabelle
Clinical Director, Cancer Immunotherapy Program (DITEP), Gustave Roussy
Immuno-oncologyEarly-phase immunotherapyMSI-high tumours
Aurélien Marabelle is the immunotherapy investigator behind the tumour-agnostic pembrolizumab data in MSI-high cancers.
Benjamin Besse
Head of Clinical Research, Gustave Roussy; thoracic oncologist
Thoracic oncologyADCs in lung cancerOncogene-driven NSCLC
Benjamin Besse is a lung cancer trialist central to the Dato-DXd and HER3-DXd lung programmes.
Caroline Robert
Head of Dermatology Unit, Gustave Roussy; Professor, Paris-Saclay University
MelanomaImmunotherapyBRAF/MEK targeted therapy
Led KEYNOTE-006 and COMBI-v, the trials that made pembrolizumab and dabrafenib-trametinib standards in melanoma.
Fabrice André
Director of Research, Gustave Roussy; Professor of Medical Oncology, Paris-Saclay
Breast cancerPrecision oncologyGenomics-driven trials
Breast cancer geneticist who led SOLAR-1 and the SAFIR precision-medicine trials; ESMO President 2025-2026.
Fabrice Barlesi
Director General, Gustave Roussy; thoracic oncologist
Thoracic oncologyImmunotherapyPrecision medicine
Fabrice Barlesi runs Europe's largest cancer centre and is a leading lung cancer trialist.
Gilles Vassal
Board member, Oncopolicy
Paediatric oncologyPaediatric drug developmentOncology policy
Gustave Roussy paediatric oncologist and past SIOPE president who leads its oncopolicy work and helped shape European paediatric medicines regulation.
Jacques Grill
Paediatric neuro-oncologist, Gustave Roussy
Paediatric high-grade gliomaDiffuse midline gliomaPaediatric brain tumour trials
Paris paediatric neuro-oncologist who led HERBY, the trial that showed adding bevacizumab does not help children with high-grade glioma, and who leads European trials in diffuse midline glioma.
Jean-Charles Soria
Professor of Medicine, Paris-Saclay; former Director General, Gustave Roussy
Early drug developmentEGFR-mutant lung cancerPhase 1 trials
Ran the phase 1 unit that pioneered many targeted therapies, and led the FLAURA trial that made osimertinib first-line.
Julien Hadoux
Endocrine oncologist, Gustave Roussy
Medullary thyroid cancerRET inhibitorsNeuroendocrine tumours
Paris endocrine oncologist who was lead author of LIBRETTO-531, the trial that showed the selective RET inhibitor selpercatinib beats older kinase inhibitors as first treatment for advanced medullary thyroid cancer.
Karim Fizazi
Head of Medical Oncology, Gustave Roussy; Professor, Paris-Saclay
Prostate cancerGenitourinary oncologyHormone therapy
Led LATITUDE and PEACE-1, which put abiraterone into first-line metastatic prostate cancer.
Laurence Albiges
Head of the Department of Medical Oncology, Gustave Roussy
Renal cell carcinomaImmunotherapyHIF-2 alpha inhibition
French kidney cancer specialist who co-led CheckMate 214 and the belzutifan trials.
Laurence Zitvogel
Research Director, INSERM U1015, Gustave Roussy
Tumour immunologyGut microbiome and immunotherapyImmunogenic cell death
Immunologist who showed that the gut microbiome shapes responses to immunotherapy and chemotherapy.
Martin Schlumberger
Emeritus Professor of Oncology, Gustave Roussy and Université Paris-Saclay
Thyroid cancerRadioiodine therapyKinase inhibitors
Led SELECT (lenvatinib) and the ESTIMABL trials that showed many thyroid cancer patients can have lower radioiodine doses or none at all.
Patricia Pautier
Medical oncologist, Gustave Roussy
LeiomyosarcomaGynaecological sarcomasOvarian cancer
Paris oncologist who led LMS-04, the trial that showed doxorubicin plus trabectedin lengthens survival in advanced leiomyosarcoma compared with doxorubicin alone.
Similar pages
- InstitutionInstitut Curie
Shares Fondation ARC pour la recherche sur le cancer, Institut Pasteur, Institut National du Cancer, Haute Autorité de Santé.
- TechnologyFaecal microbiota transplantation for PD-1 non-responders
Shares Laurence Zitvogel, Take faecal transplant plus immunotherapy to a definitive trial, Microbiome transplant as a routine immunotherapy adjunct, Microbiome-tumour interactions.
- InstitutionSIOP Europe (European Society for Paediatric Oncology)
Shares Gilles Vassal, Inter-B-NHL Ritux 2010, Innovative Therapies for Children with Cancer (ITCC), Sarcomas (soft tissue, bone, GIST).
- TrialFMT plus pembrolizumab in anti-PD-1-refractory melanoma (Pittsburgh)
Shares Take faecal transplant plus immunotherapy to a definitive trial, Microbiome transplant as a routine immunotherapy adjunct, Microbiome-tumour interactions.
- PersonPamela Kearns
Shares Gilles Vassal, Innovative Therapies for Children with Cancer (ITCC).
- InstitutionPrincess Máxima Center for Pediatric Oncology
Shares Alexander Eggermont, Innovative Therapies for Children with Cancer (ITCC), Sarcomas (soft tissue, bone, GIST).
cancers
technologies
drugs
ApprovedADC
Datopotamab deruxtecan · Datroway
ApprovedADC
Trastuzumab deruxtecan · Enhertu
companies
institutions
pathways
trials
ideas
A global first-in-human network for academic cancer trials with single ethics reviewA mandatory trial line in every tumour board recommendationGive immunotherapy in the morningMicrobiome transplant as a routine immunotherapy adjunctTake faecal transplant plus immunotherapy to a definitive trialWhat actually holds T cells at the tumour border?
people
key papers
Open-source projects
All open source in oncology →Open-source projects that this organisation maintains, from OnCo's own catalogue: licence and last activity as the repository reported them on the day of the fetch. Listing is not endorsement; check the licence before reuse and the validation before clinical use.
Gustave Roussy's technology-agnostic pipeline for spatial omics: segmentation, annotation and visualisation for Xenium, MERSCOPE, CosMx and imaging.